StemCell Therapy

NEW YORK, Sept. 1, 2020 /PRNewswire/ -- Peloton (NASDAQ: PTON), the world's largest interactive fitness platform, today announced the formation of the Peloton Health and Wellness Advisory Council, which will work closely with the company as it continues to look at how it can positively impact the physical, mental and emotional wellbeing of its community of Members from around the world. Peloton will collaborate with the council, which includes five renowned doctors, researchers and other medical professionals from the fields of cardiovascular medicine, cardiopulmonary exercise, neurology and neuroscience, and draw on their knowledge and expertise to help inform product and content development, community-focused and social impact initiatives, research projects and more.

"We constantly hear from our Members that Peloton has not only profoundly impacted their physical, mental and emotional health, but has also helped them cope with issues ranging from neurodegenerative disease or cancer, to PTSD or post-partum depression," said William Lynch, president, Peloton. "With the addition of this esteemed Health and Wellness Advisory Council, which includes some of the best minds in medicine, we can leverage scientific research and medical expertise to help us better serve our community through our content, products and platform."

The Peloton Health and Wellness Advisory Council includes the following experts:

Cardiovascular MedicineSuzanne Steinbaum, MD:Dr. Suzanne Steinbaum is an attending cardiologist, specializing in prevention. She has recently opened a private practice in New York City, at the Juhi-Ash integrative health center encompassing heart health, wellness and prevention, as well as the effects of stress and inflammation on heart health. She is the founder and President of SRSHeart, a personalized lifestyle management program using anatomy, physiology, functional data, genetics and metabolism, along with technology to reach ultimate cardiovascular health. She has been the Director of Women's Cardiovascular Prevention, Health and Wellness at Mt. Sinai Heart in New York City, after being the Director of Women's Heart Health at Northwell Lenox Hill. Dr. Steinbaum is a Fellow of the American College of Cardiology and the American Heart Association. She is a National Spokesperson for the Go Red for Women campaign and chairperson of the Go Red for Women in New York City. She is on the New York City Board of the American Heart Association and on the Scientific Advisory Board of the Women's Heart Alliance.

NeurologyRichard S. Isaacson, MD:Richard S. Isaacson, M.D. is a Neurologist, clinician and researcher who specializes in Alzheimer's prevention and treatment. He previously served as Associate Professor of Clinical Neurology, Vice Chair of Education, and Education Director of the McKnight Brain Institute in the Department of Neurology at the University of Miami (UM) Miller School of Medicine. Prior to joining UM, he served as Associate Medical Director of the Wien Center for Alzheimer's disease and Memory Disorders at Mount Sinai. Dr. Isaacson specializes in Alzheimer's disease (AD) risk reduction and treatment, mild cognitive impairment due to AD and preclinical AD. His clinical research has shown that individualized clinical management of patients at risk for AD dementia is an important strategy for optimizing cognitive function and reducing risk of dementia. He has also published novel methods on using a precision medicine approach in real-world clinical practice. He has also led the development of Alzheimer's Universe (AlzU.org) a vast online education research portal on AD with results published in the Journal of the Prevention of Alzheimer's disease, Journal of Communication in Healthcare, Alzheimer's & Dementia: Translational Research & Clinical Interventions, and Neurology. With a robust clinical practice and broad background in computer science, m-Health, biotechnology and web-development, Dr. Isaacson is committed to using technology and lifestyle interventions (such as physical exercise and nutrition) to optimize patient care, AD risk assessment and early intervention.

Vernon Williams, MD:Vernon Williams, MD is the Founding Director of the Center for Sports Neurology and Pain Medicine at Cedars-Sinai Kerlan-Jobe Institute in Los Angeles, CA. Dr. Williams is a former Commissioner for the California State Athletic Commission and current Chair of Neurological Health for the Commission's Medical Advisory Committee, as well as a former two-term Chair of the American Academy of Neurology Sports Neurology Section. He serves as a neurological medical consultant to local professional sports organizations such as the Los Angeles Rams, Los Angeles Dodgers, Los Angeles Lakers, Los Angeles Kings and Los Angeles Sparks. He also assists local colleges and numerous high school and youth sports/club athletic teams in this capacity. Dr. Williams is a board-certified clinical neurologist with very specialized areas of subspecialty: Sports Neurology and Pain Medicine. He is actively engaged in researching and developing innovative and effective treatments and technologies that help people recognize symptoms of a neurological injury sooner so that the work of treating them can happen faster, and with less potential for permanent damage. He passionately advocates for optimization of Neurological Health across the lifespan for his patients and peak performance clients.

Cardiopulmonary ExerciseAimee M. Layton, PhD:Aimee Layton, PhD is an Assistant Professor of Applied Physiology in Pediatrics in the Division of Pediatric Cardiology and the Director of the Pediatric Cardiopulmonary Exercise Laboratory at Columbia University Medical Center / New York Presbyterian Hospital. Dr. Layton recently joined the pediatric cardiology team after being director of the adult pulmonary exercise laboratory for a decade. This cross discipline experience provides Dr. Layton with knowledge of both how the lungs and the heart respond to exercise and the role of disease and sports in both adults and kids. Dr. Layton's prior research investigated respiratory biomechanics, with publications in both diseased and healthy populations. Her new research focuses on bridging the gap between the lab and the home, in hopes of impacting kids' behavior and relationship with exercise. Dr. Layton is a respected expert in clinical exercise physiology and has lectured internationally on the topic. Beyond her research, Dr. Layton has been performing exercise testing and counseling for both patients with lung disease and patients with heart disease. She plays an important role as one of the lead exercise physiologists for Columbia University Medical Center in testing, exercise counseling and research.

NeuroscienceJay Alberts, PhD:As a Cleveland Clinic Scientist, Ph.D., Jay Alberts' research is aimed at understanding the structure-function relationships within the central nervous system and evaluating the impact of behavioral and surgical interventions to improve motor and non-motor function in Parkinson's disease, stroke, Alzheimer's and other neurological populations. Human studies are currently ongoing to address these basic and translational research questions. Dr. Alberts is developing and validating new methods of using exercise and augmented and virtual reality to engage patient populations remotely. He is currently leading two multi-site clinical trials investigating the role of exercise in slowing the progression of Parkinson's disease. Dr. Alberts has led multiple successful technology initiatives aimed at better understanding patient symptoms and communicating these symptoms to providers. He is currently building AR and VR applications as prescriptive digital therapeutic systems for neurological patients. To date, Dr. Alberts has written 100 peer reviewed articles, has had uninterrupted extramural funding since 1999 and holds 10 patents.

For more information about Peloton or the Peloton Health and Wellness Advisory Council, please visit http://www.blog.onepeloton.com.

About PelotonPeloton is the largest interactive fitness platform in the world with a loyal community of more than 2.6 million Members. The company pioneered connected, technology-enabled fitness, and the streaming of immersive, instructor-led boutique classes for its Members anytime, anywhere. Peloton makes fitness entertaining, approachable, effective, and convenient, while fostering social connections that encourage its Members to be the best versions of themselves. An innovator at the nexus of fitness, technology, and media, Peloton has reinvented the fitness industry by developing a first-of-its-kind subscription platform that seamlessly combines the best equipment, proprietary networked software, and world-class streaming digital fitness and wellness content, creating a product that its Members love. The brand's immersive content is accessible through the Peloton Bike, Peloton Tread, and Peloton App, which allows access to a full slate of fitness classes across disciplines, on any iOS or Android device, Apple TV, Fire TV, Roku TVs, and Chromecast and Android TV. Founded in 2012 and headquartered in New York City, Peloton has a growing number of retail showrooms across the US, UK, Canada and Germany. For more information, visit http://www.onepeloton.com.

SOURCE Peloton

http://www.pelotoncycle.com

More:
Peloton Introduces Its First-Ever Health And Wellness Advisory Council - PRNewswire

EAGAN, Minn., Sept. 01, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (AI”) to personalized medicine and drug discovery, today announced that management, will present at the LD Micro's "LD 500" Virtual Investor Conference, on Wednesday, September 02, 2020 3:40 PM Eastern Time.

A live webcast of the presentation will be available to the public at https://www.webcaster4.com/Webcast/Page/2019/36691. The webcast will be archived for 90 days following the live presentation.

About Predictive Oncology Inc.

Predictive Oncology (NASDAQ: POAI) operates through three segments (Domestic, International and other), which contain four subsidiaries; Helomics, TumorGenesis, Skyline Medical and Skyline Europe. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. Helomics’ CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions, by providing an evidence-based roadmap for therapy. In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor, patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary bioinformatics platform to provide a tailored solution to its clients’ specific needs. Predictive Oncology’s TumorGenesis subsidiary is developing a new rapid approach to growing tumors in the laboratory, which essentially fools” cancer cells into thinking they are still growing inside a patient. Its proprietary Oncology Discovery Technology Platform kits will assist researchers and clinicians to identify which cancer cells bind to specific biomarkers. Once the biomarkers are identified they can be used in TumorGenesis’ Oncology Capture Technology Platforms which isolate and help categorize an individual patient’s heterogeneous tumor samples to enable the development of patient specific treatment options. Helomics and TumorGenesis are focused on ovarian cancer. Predictive Oncology’s Skyline Medical division markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. The company has achieved sales in five of the seven continents through both direct sales and distributor partners. For more information, please visit http://www.Predictive-Oncology.com.

Forward-Looking Statements

Certain matters discussed in this release contain forward-looking statements. These forward-looking statements reflect our current expectations and projections about future events and are subject to substantial risks, uncertainties and assumptions about our operations and the investments we make. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, future financial position, future revenue and financial performance, projected costs, prospects, plans and objectives of management are forward-looking statements. The words anticipate,” believe,” estimate,” expect,” intend,” may,” plan,” would,” target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Our actual future performance may materially differ from that contemplated by the forward-looking statements as a result of a variety of factors including, among other things, factors discussed under the heading Risk Factors” in our filings with the SEC. Except as expressly required by law, the Company disclaims any intent or obligation to update these forward-looking statements.

Investor Relations Contact:

Hayden IR James Carbonara (646)-755-7412 james@haydenir.com

Read the original post:
Predictive Oncology Inc to Present at LD Micro's "LD 500" Virtual Investor Conference on Wednesday, September 02, 2020 3:40 PM Eastern Time...

Precision Medicine Market Trends, In-Depth Research on Market Size, Emerging Growth Factors, Global 2020 Trends and Forecasts 2025

The Precision MedicineMarket report is one of the most comprehensive and important dataabout business strategies, qualitative and quantitative analysis of Global Market.It offers detailed research and analysis of key aspects of the Precision Medicinemarket. The market analysts authoring this report have provided in-depth information on leading growth drivers, restraints, challenges, trends, and opportunities to offer a complete analysis of the Precision Medicinemarket.

The researchers have considered almost all important parameters for company profiling, including market share, recent development, gross margin, future development plans, product portfolio, production, and revenue. The report includes detailed analysis of the vendor landscape and thorough company profiling of leading players of the Precision Medicine market.

Get PDF sample copy of this report(Including impact of Covid-19)@: https://www.marketinforeports.com/Market-Reports/Request-Sample/161616

Top Leading players covered in the Precision Medicine market report: Johnson & Johnson, IBM, GE Healthcare, Illumina, Roche, Laboratory Corporation of America Holdings, Thermo Fisher Scientific, Novartis, Abbott Laboratories, Almac Group, Intel Corporation, Biomrieux Sa, Cepheid, Qiagen, Randox Laboratories, Healthcore and More

Key Types:DiagnosticsTherapies

Key End-Use:OncologyNeurosciencesImmunologyRespiratoryOthers

The global Precision Medicine market is analyzed across key geographies namely: North America, Europe, Asia-Pacific, South America, Middle East and Africa. Each of these regions is analyzed on basis of market findings across major countries in these regions for a macro-level understanding of the market.

The latest report added by Market Info Reportsdemonstrates that the global Precision Medicine market will showcase a steady CAGR in the coming years. The research report includes a thorough analysis of market drivers, restraints, threats, and opportunities. It addresses the lucrative investment options for the players in the coming years. Analysts have offered market estimates at a global and regional level.

Major Points Covered in TOC:

Overview: Along with a broad overview of the global Precision Medicine market, this section gives an overview of the report to give an idea about the nature and contents of the research study.

Analysis on Strategies of Leading Players: Market players can use this analysis to gain competitive advantage over their competitors in the Precision Medicine market.

Study on Key Market Trends: This section of the report offers deeper analysis of latest and future trends of the Precision Medicine market.

Market Forecasts: Buyers of the report will have access to accurate and validated estimates of the total market size in terms of value and volume. The report also provides consumption, production, sales, and other forecasts for the Precision Medicine market.

Regional Growth Analysis: All major regions and countries have been covered in the report. The regional analysis will help market players to tap into unexplored regional markets, prepare specific strategies for target regions, and compare the growth of all regional markets.

Segmental Analysis: The report provides accurate and reliable forecasts of the market share of important segments of the Precision Medicine market. Market participants can use this analysis to make strategic investments in key growth pockets of the Precision Medicine market.

For More Information:https://www.marketinforeports.com/Market-Reports/161616/Precision-Medicine-market

The study objectives are:

Customization of the Report:

Market Info Reports provides customization of reports as per your need. This report can be personalized to meet your requirements. Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.

Get Customization of the [emailprotected]:https://www.marketinforeports.com/Market-Reports/Request-Customization/161616/Precision-Medicine-market

Contact Us:Mr. Marcus KelCall: +1 415 658 9988 (International)+91 84 839 65921 (IND)Email: [emailprotected]

Original post:
Precision Medicine Market Analysis By Distribution Channel, Region And Forecast From 2020 To 2025|Johnson & Johnson, IBM, GE Healthcare, Illumina,...

Trusted Business Insights answers what are the scenarios for growth and recovery and whether there will be any lasting structural impact from the unfolding crisis for the Precision Medicine market.

Trusted Business Insights presents an updated and Latest Study on Precision Medicine Market 2019-2029. The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market.The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the Precision Medicine market during the forecast period (2019-2029).It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary, and SWOT analysis.

Get Sample Copy of this Report @ Precision Medicine Market Research Report Forecast to 2029 (Includes Business Impact of COVID-19)

Abstract, Snapshot, Market Analysis & Market Definition: Precision Medicine MarketIndustry / Sector Trends

Precision Medicine Market size was valued at USD 52.6 billion in 2018 and is expected to witness 10.5% CAGR from 2019 to 2025.

U.S.Market Segmentation, Outlook & Regional Insights: Precision Medicine Market

Precision Medicine Market, By Technology, 2018 & 2025 (USD Million)

Growing demand and advancements in cancer biology will drive personalized medicine market during the forecast period. Accessibility to large-scale human genome database including next-generation sequencing (NGS) and computational tools foster industry growth. Development of innovative genetic technologies examines the functional effect of genetic makeup that leads in developing cancer, thus, should propel huge demand for cancer biology. Several such tools are widely used to study the mechanism of DNA repair, epigenetic changes related to cancer and gene regulation in cancerous cells that offer opportunities for cancer biology in personalized medicine.

Moreover, improving efficiencies within the health care system will serve to be positive impact rendering factor personalized treatment business growth. Benefits offered by personalized medicines and treatment includes target treatment for patient, optimal dosing, focus on prevention and earlier intervention as well as preventing adverse events. Thus, above mentioned features will foster the demand for personalized medication market growth. However, high cost associated with precision medicine may impede industry growth over the forecast period.

Precision Medicine Market, By Technology

Drug discovery segment held over 21% revenue share in 2018 and is projected to grow significantly by 2025. Focus of business players on developing technologically advanced drugs enabling superior treatment for several life-threatening diseases will create segmental growth opportunities. Bio-pharmaceutical companies utilize bioinformatics software to introduce customized novel drugs that should augment the segmental growth.

Gene sequencing segment is anticipated to show exponential CAGR of around 11% over the coming years. Benefits offered by gene sequencing technique such as relevant information about patients genome and biological research ensures quick drug discovery process that should boost segmental growth.

Precision Medicine Market, By Application

Immunology segment accounted for over USD 9.5 billion in 2018 and is estimated to witness considerable growth trend during the analysis period. Growing demand for bioinformatics and big data analytics to segregate human genome data obtained from immunological processes favors segmental growth.

Oncology segment held significant revenue share in 2018 and is assessed to show more than 10.5% CAGR during the forecast period. Segment growth is attributable to increasing prevalence of cancer cases resulting in development of innovative drugs with specific drug formulations in precision medicine.

Germany Precision Medicine Market Size, By Application, 2018 (USD Million)

Precision Medicine Market, By End-use

Healthcare IT companies segment held more than 27% revenue share in 2018 and will show lucrative growth over coming years. Increasing demand for developing technologically advanced tools for rapid integration, storage, and analysis of patient data should augment the business growth.

Diagnostic companies segment was valued around USD 9.5 billion in 2018. Such companies provide solutions that bridges the gap between clinical needs of patients and technology. Various benefits such as high quality of the medical diagnostic devices enabling precise patient management will foster industry growth.

Precision Medicine Market, By Region

North America precision medicine market is predictable to show around 9% CAGR over the analysis period. Rising prevalence of respiratory and oncology diseases as a result of lifestyle changes is the key factor driving demand for market. Rising healthcare expenditure coupled with presence of major industry players in North America will spur the business growth.

Asia Pacific precision medicine industry was valued more than USD 11 billion revenue in 2018. Regional growth can be attributed to technological advances in sequencing technology. Moreover, presence of large patient pool in Asia Pacific along with growing investments in R&D activities will accelerate personalized medication business growth.

MEA Precision Medicine Market Size, By Country, 2025 (USD Million)

Key Players, Recent Developments & Sector Viewpoints: Precision Medicine Market

Few of the prominent industry players operating in precision medicine industry include Biocrates Life Sciences, Tepnel Pharma Services, Qiagen, Menarini Silicon Biosystems, Novartis, NanoString Technologies, Pfizer, Eagle Genomics, Quest Diagnostics, Roche, Intomics, and Teva Pharmaceutical. The business players implement several strategies including acquisitions, partnerships and innovative product enhancement to capitalize on market growth opportunities.

Recent industry developments:

In October 2018, Eagle Genomics partnered with Microsoft Genomics to tackle computational challenges of genomics era. This partnership aimed to inculcate scale and power of cloud to precision medicine, across the production of fundamental research and core services.

In January 2018, Syapse collaborated with Roche in order to advance precision medicine in oncology. Also, this partnership focuses on clinical delivery and product development for introducing precision medicine to more patients.

Precision Medicine Industry Viewpoint

History of precision medicine can be tracked back in 1950s when Watson and Crick discovered the structure of the DNA as double-helix. Efforts to supplement the DNA structure, researchers cracked the genetic code in early 1960s. Additionally, introduction of the first DNA sequencing technology was developed in 1970s where researchers discovered first enzyme linked to individual variation in response to dosing. In early 1980s Polymerase Chain Reaction (PCR) was first discovered allowing for fast amplification of DNA sequences. These advances continued in 1990s where human genome project was launched along with FDA approval for first personalized medicine with a companion diagnostic, for the treatment of HER2 positive breast cancer. Such form of advancements continued in 2000s where first targeted therapies for lung cancer, leukemia, melanoma, cystic fibrosis, HIV, and other diseases accelerated tremendous growth opportunities for precision medicine. Moreover, increasing demand for personalized medication for secured patient management will drive industry growth during the forthcoming years

Key Insights Covered: Exhaustive Precision Medicine Market1. Market size (sales, revenue and growth rate) of Precision Medicine industry.2. Global major manufacturers operating situation (sales, revenue, growth rate and gross margin) of Precision Medicine industry.3. SWOT analysis, New Project Investment Feasibility Analysis, Upstream raw materials and manufacturing equipment & Industry chain analysis of Precision Medicine industry.4. Market size (sales, revenue) forecast by regions and countries from 2019 to 2025 of Precision Medicine industry.

Research Methodology: Precision Medicine Market

Looking for more? Check out our repository for all available reports on Precision Medicine in related sectors.

Quick Read Table of Contents of this Report @ Precision Medicine Market Research Report Forecast to 2029 (Includes Business Impact of COVID-19)

Trusted Business InsightsShelly ArnoldMedia & Marketing ExecutiveEmail Me For Any ClarificationsConnect on LinkedInClick to follow Trusted Business Insights LinkedIn for Market Data and Updates.US: +1 646 568 9797UK: +44 330 808 0580

Read more:
Precision Medicine Market: Trends, Applications, Industry Competitive Analysis, Growth,Forecast: 2019 to 2029 - The Scarlet

MINNEAPOLIS, Aug. 25, 2020 /PRNewswire/ -- Revel Health, a Minneapolis-based next-gen healthcare technology company, and Coriell Life Sciences (CLS), a Philadelphia-based bioinformatics company and leading provider of genetic interpretation and reporting, today announced a partnership designed to drive healthier action for Medicare Advantage members in relation to how their genes impact the effectiveness and efficacy of prescribed medications.

Today, about one-fifth of medications prescribed to elderly patients are inappropriate, and the safety and efficacy of more than 200 drugs are known to be impacted by a person's genes. Coriell Life Sciences specializes in precision medicine through pharmacogenetics, or the study of how people respond differently to drug therapy based upon their genetic makeup,and offers genetic panel testing for medication response. The genetic panel testing aims to help members understand how medications impact them based on their DNA.

"We're excited to work with Coriell Life Sciences on this new initiative to empower members to take action to understand how medications personally impact them," said Jeff Fritz, CEO of Revel Health. "CLS is committed to helping members understand how their genes can impact a response to certain medications, and this commitment shows in their desire to use the latest tools and techniques in driving healthier action."

Utilizing Revel Connect, Revel Health's health action platform, CLS and Revel Health have partnered to communicate the genetic testing offering to members and build a multi-channel program aimed to drive members to take action to understand their personal medication risk.

Revel Health and CLS launched the first wave of a program in June to reach more than 22,000 Medicare Advantage members via a multi-channel approach including text, email, interactive voice (IVR) and mail to communicate the importance of DNA testing for medication efficacy and to drive members to work with CLS to get tested.

"Each year there are more than 275,000 deaths attributable to medication errors and the reality is that medications impact each of us differently based on our genetics," said Scott Megill, President and CEO at Coriell Life Sciences. "Our goal is to protect the most vulnerable, and Revel Health was a natural digital partner in helping us to deliver on this goal. Revel Health's platform has enabled us to communicate with vulnerable populations and grow their understanding of the impact of medications they're taking based on their genetics."

Revel Connect, Revel Health's platform uses data science, behavioral research, and multi-channel tools to investigate the social barriers and personal attributes that impact health plan members to take action to complete a DNA test. Then, based on each member's unique needs, Revel Health's advanced technology builds targeted multi-channel digital communications that prompt members to engage with resources and take health action in real time, ultimately driving healthier outcomes in relation to medication risk.

About Revel Health

Revel Health is a healthcare technology company that is reinventing health engagement to make it better through its industry-leading health action platform, Revel Connect. Revel Health helps healthcare organizations connect with members and patients in a personalized way to build better healthcare consumer experiences, drive positive health action, and improve health outcomes. Follow Revel Health onTwitter and connect with us onLinkedIn. Learn more about who we are and our approach by visiting us atRevel-Health.com.

About Coriell Life Sciences (CLS)Coriell Life Sciences (CLS) is a trusted advisor in genetic science. On the cutting edge of precision medicine, we partner with customers to provide actionable solutions, informed by genetic knowledge, to reduce healthcare costs and empower a healthier world. We bridge the gap between genetic knowledge and clinical application. Coriell Life Sciences sets the gold standard in genetic interpretation and reporting and offers the most comprehensive medication risk management program on the market. Visit coriell.com, email [emailprotected] or follow @CoriellLife.

SOURCE Revel Health

Home

Continued here:
Revel Health and Coriell Life Sciences Partner to Drive Members to Take Action for Medication Risks - PRNewswire

The National Human Genome Research Institute definesgenomic medicine asan emerging medical discipline that involves using genomic information about an individual as part of their clinical care (e.g., fordiagnostic or therapeutic decision-making) and the health outcomes and policy implications of that clinical use. Genomic medicine is a type of precision medicine in which genomics, epigenomics and other related data is used to accurately aid in individual disease diagnosis. Genomic medicine has novel applications in the fields of oncology, pharmacology, rare and undiagnosed diseases, and infectious disease.Genomic medicine paves way for personalized medicine into clinics and has immense potential to reach the physicians and patients. Genomic medicine has been used for advanced sequencing in cancer pharmacogenomics, rare disorder diagnosis and for tracking of outbreaks of infectious diseases.

Genomic Medicine Market: Drivers & Restraints

Backed by government investments in precision medicine initiatives such as a multimillion dollar investment by President Obama in January 2015 which aims to improve how to treat and prevent a disease by laying emphasis on its genetic makeup is expected to boost the market growth. Clinical validity and utility of genomic medicine tests is a major issue witnessed in the global market. Also, lack of awareness among healthcare professionals, sluggish adoption of genome medicine, fluctuating regulatory landscape are the factors which could hamper growth of the global genomic medicine market.

To remain ahead of your competitors, request for a sample [emailprotected]

https://www.persistencemarketresearch.com/samples/11323

Genomic Medicine Market: Segmentation

The global genomic medicine market is classified on the basis of application type, end use and region.

Based on application, the global genomic medicine market is segmented into the following:

Based on end use, the global genomic medicine market is segmented into the following:

To receive extensive list of important regions, Request Methodology here @

https://www.persistencemarketresearch.com/methodology/11323

Genomic Medicine Market: Overview

Genomic medicine is gaining momentum with expanding applications ranging from risk assessment and diagnosis in healthy individuals to genome-based treatment for patients with complicated disorders. Oncology is a major application of genomics medicine during cancer screening process as diagnostics for genetic and genomic markers. Oncology segment is expected to account for a major share in the global genomic medicine market. Genomic medicine is increasingly being used not only for research purpose but also in clinical applications. In clinical applications, genomic medicine will potentially enhance patient care.

Genomic Medicine Market: Region wise Overview

Geographically, global Genomic Medicine market is classified into regions viz. North America, Latin America, Western Europe, Eastern Europe, Asia Pacific Excluding Japan (APEJ), Japan, Middle East and Africa (MEA). Owing to the presence of large number of academic as well as research institutions in the U.S. which are working on genomic medicine to discover next-generation genomic medicines, North America region is projected to lead the global genomic market in terms of value during the forecast period. Also, the presence of several universities offering educational programs coupled with opportunities in scientific research of genomic medicine in the North America and Europe is expected to have positive impact on the regional markets. The genomic medicine concept still in its nascent stage is yet to receive an impetus from the emerging market which are anticipated to hold smaller shares in the global market.

Genomic Medicine Market: Key Players

The key research institutes in global genomic medicine market are BioMed Central Ltd., Cleveland Clinic, The University of Texas MD Anderson Cancer Center, The Manchester Centre for Genomic Medicine, Center for Genomic Medicine to name a few. The focus of the top players will be on the identification of effective drug candidates particularly in cancer treatment based on the molecular structure of tumors.

You Can Request for TOC Here @

https://www.persistencemarketresearch.com/toc/11323

Explore Extensive Coverage of PMR`s

Life Sciences & Transformational HealthLandscape

About us:

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics andmarket research methodologyto help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMRs collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.

Contact us:

Naved BegPersistence Market ResearchAddress 305 Broadway, 7th FloorNew York City,NY 10007 United StatesU.S. Ph. +1-646-568-7751USA-Canada Toll-free +1 800-961-0353Sales[emailprotected]Websitehttps://www.persistencemarketresearch.com

Continued here:
Global Genomic Medicine Market to Witness Heightened Growth During the Period 2017 2025 - Scientect

As the global pandemic drags on, many of us are more stressed out than usual. And that often means scoring a lot less sleep at night.

"Trying to get good sleep while you're stressed out is like trying to make a half-court shot while blindfolded," said Michael Breus, a clinical psychologist in Los Angeles. Breus focuses on insomnia and high-performance sleep coaching, a three- to six-month program for CEOs, athletes and celebrities.

"You can do it, but it's really tough to pull off."

Let's say you have been feeling extra overwhelmed lately. That, Breus said, prompts your body to release cortisol, the primary stress hormone. This coincides with sugar (or glucose) entering the bloodstream, which elevates your blood pressure.

Next thing you know, Breus said, your muscles tense up, your heart pumps faster and your brain kicks into overdrive. It's the old fight-or-flight response you learned about in grade school. In other words, your body is now in survival mode.

That is what makes falling asleep very tricky.

When that stress persists week after week, the body adjusts to the higher cortisol levels. This continues to prevent you from getting quality shut-eye but can also lead to serious problems like heart disease, hypertension, diabetes and depression, according to Breus.

Enter these sleep-focused apps.

We use apps for just about everything, so why not use them to help us out when it comes to sleep, right? Perhaps. It depends on what type of sleep issue you are having, since Breus said there are 88 different sleep disorders.

"I think that apps will be helpful for people to manage stress, become educated and learn about their sleep environment," Breus said.

When looking for an app, first consider what is keeping you from sleeping and what the app is going to address. Do you need to quiet your noisy environment, ease your stress levels or address a diagnosed condition?

Make sure to think of it as a tool, not as a stand-alone solution that can solve your unique situation. And keep in mind, it's best to place the phone face down so the screen light doesn't bother you. For most of the apps, you can also download content and put your phone in airplane mode, so you won't receive calls or texts while attempting to snooze.

Here are some expertly curated apps, chosen by Breus and New York City-based psychologist Joshua Tal, who specializes in treating sleep disorders.

If your sleep issues persist, make sure to consult with your doctor for personalized medical advice. Many medical professionals are offering telehealth services during the pandemic.

Subscribe to CNN's Sleep, But Better Newsletter: Want the best sleep of your life? Sign up for our newsletter series for helpful hints to achieve better sleep.

Some relaxation apps lull you into dreamland with sounds of the Amazon rainforest or monitor your sleep habits throughout the night. Others incorporate meditation to help reduce stress levels before bedtime. And some, designed specifically for insomniacs, require a prescription.

"I usually recommend nature and white-noise apps for clients that have a snoring bed partner or loud noises outside," Tal said.

Portal ($29.99 per year), for example, is an app that uses immersive 3D sounds -- think gentle waves in Hawaii, a log fire in Switzerland or a whale encounter in Tahiti -- as a way to help you get ready for bed.

"It can be a good wind-down, pre-bedtime activity," Tal said.

Other noise-blocking apps include White Noise Generator, Relax Melodies and myNoise.

Breus said he's impressed with Pzizz ($9.99 per month), an app that uses binaural beats, with two different frequencies played in each ear. Plus, there is a man's voice encouraging you to relax. Don't worry: You can mute this if you'd like. The user can also schedule bedtime reminders, as well as nap reminders.

BrainTap Pro ($9.99 per month), another mobile app that Breus recommended, is designed to retrain the brain and also incorporates binaural beats. This one combines those beats with guided visualization, 10-cycle holographic music (a sonic technology that produces a 360-degree sound environment) and isochronic tones, which are equal-intensity pulses of sound followed by moments of silence. It's all meant to create a balanced brainwave state.

Headspace and Calm, recommended by Tal, offer sleep mediations and relaxation exercises.

Headspace ($12.99 per month) includes sleepcasts, a 45-minute audio recording (think of it as a bedtime story) that uses sound, breathing exercises and visualization to help put you in a tranquil mood.

There are also sleep music, wind-down activities, soundscapes and guided exercises to help with waking up in the night. The 45- to 55-minute audio sessions aim to help you visualize a calm scene.

The Calm app ($69.99 per year) is similar. Users choose from more than 100 hours of soothing music, guided meditations and narrated sleep stories by celebrities like Kelly Rowland, Lucy Liu and Matthew McConaughey.

Likewise, Restflix ($7.99 per month), which Breus recommended, is a streaming service with hundreds of hours of sleep meditations, bedtime stories, serene landscapes, binaural beats and nature sounds to help people develop better sleep habits.

Tal said sleep-tracking apps such as Sleep Cycle, Sleep Genius, Sleep Score and Pillow can be helpful for those with mild sleep issues as a way to improve sleep environment and regimen. These apps certainly won't give you the results you'd get by visiting a traditional sleep center, but they can help identify patterns.

When it comes to complicated sleep issues like insomnia and sleeplessness, Breus said, online digital coaching options offer a targeted approach, help pinpoint problems and have great data supporting them.

Somryst, a nine-week prescription digital therapeutic for chronic insomnia, which will be commercially available in the third or fourth quarter of 2020, must by prescribed and monitored by a licensed health care provider. It uses technology to deliver cognitive behavioral therapy for insomnia digitally through a smartphone or a tablet.

Similar to traditional face-to-face CBT-I, Somryst uses tailored sleep restriction and consolidation; stimulus control; and personalized cognitive restructuring to improve insomnia symptoms. Along with that, there is a clinician-facing dashboard to track patient treatment and progress.

Cognitive behavioral therapy for insomnia has been recommended as the first-line treatment for chronic insomnia since 2016 by the American College of Physicians and the American Academy of Sleep Medicine.

"Somryst is the first FDA market authorized prescription digital therapeutic intended to treat patients age 22 years of age and older with chronic insomnia and the only FDA authorized therapeutic that delivers guideline recommended first-line treatment for chronic insomnia," said Dr. Yuri Maricich, chief medical officer at Pear Therapeutics, the company that created Somryst.

Whether you need to block out that barking dog next door or need help coaxing your mind to slow down, there is certainly an app to address the issue. But don't be discouraged if it's tough to figure out right away. Sleep is complicated, said Breus, and there are many reasons a person could have insomnia like stress or work schedule. Apps will never cover all these factors or even most of them.

"An app may be designed for one or two aspects of a person's problem," he said, "but none of these are personalized, like a person would have in a session with a therapist."

Seeking help from a sleep psychologist first can be the best approach so that a specialist pinpoints the problem and guides you toward the right apps.

More here:
Searching for more zzzs? There is a sleep app for that - WKTV

Wellness describes itself as complete physical mental and social well-being. It comprises all the components used to lead a healthy life. Wellness is multidirectional and constitutes social, emotional, physical, spiritual, intellectual and emotional wellbeing. According to National Wellness Institute, two more component of wellness includes cultural and environmental wellness. Mental health and well-being are an integral and essential component of health. Wellness goes further than disease or disability and highlights the maintenance and improvement of health and well-being of the person. Wellness includes activities that improve health, enhance the quality of life and increase the levels of well-being of the person. Different types of wellness include workplace wellness, wellness tourism, lifestyle wellness and others. In order to help prevent disease, reduce stress, and enhance the overall quality of life Global Wellness Institute (GWI) organizes e Global Spa & Wellness Summit (GSWS) annually, that brings together leaders and visionaries to discuss various aspects of health and wellbeing.

To remain ahead of your competitors, request for a sample[emailprotected]https://www.persistencemarketresearch.com/samples/18787

Nowadays, people are focusing on preventive, proactive aspects of wellness, wellness economy incorporates industrial sector that enables consumers to incorporate wellness into their lives. Consumers are inclining towards preventive measures to prevent diseases and maintain good health. The key sector of wellness includes wellness tourism, fitness, complementary & alternative medicine, lifestyle wellness, rejuvenation and spa industry, workplace wellness and others.

Wellness is self-responsibility and is opening new opportunities for wellness market as due to increase in geriatric population, rise in disease population due to sedentary lifestyle, new research on wellness procedures using alternative medicines, expansion of consumer base and wellness industries, tourism is growing, that will incorporate wellness into travel, shift of consumers towards personal care products are some of the factors that will drive the medical wellness market. The awareness about medical wellness will help consumers, spread wellness to homes and their workplace and help the right way to exercise, include healthy eating in their diet, focus on preventive and personalized health and others. Lack of awareness about medical wellness, rise in products and services of wellness industry, lack of workforce and others are some of the factors restraining the market growth.

To receive Methodology request here @https://www.persistencemarketresearch.com/methodology/18787

The global medical wellness market is segmented on basis of wellness sector, distribution channel and geography:

Segment by Wellness Sector

Segment by Distribution Channel

The global medical wellness market is segmented into wellness sector and distribution channel. Based on the wellness sector, the medical wellness market is segmented into complementary and alternative medicine, beauty care and anti-aging (surgical and non-surgical), preventative and personalized medicine, healthy eating, nutrition and weight loss, rejuvenation and others. The beauty care and anti- aging segment will dominate the wellness market due to rise in number of aesthetics procedures and increase in number of beauty care wellness sectors. Based on the end user, the medical wellness market is segmented as franchise and company owned outlets. The global medical wellness market is going to increase significantly is near future due to shift of consumers towards proactive approaches and include wellness in day to day life

To receive extensive list of important regions, Request TOC here @https://www.persistencemarketresearch.com/toc/18787

By regional presence, the global medical wellness market is segmented into five broad regions viz. North America, Latin America, Europe, Asia-Pacific, and the Middle East & Africa. North America market is expected to dominate in terms of revenue share, owing to the high availability of advanced products and services, wellness tourism, expenditures growth, , increasing penetration of leading companies in the region along with increase in patient population. Significant economic development has led to an increase in healthcare availability in Asia Pacific region, growing number of multi-specialty care centers, rejuvenation and fitness centers and penetration of global players in Asia is expected to fuel the medical wellness market

Some of the major players in medical wellness market are Enrich Hair & Skin Solutions, VLCC Wellness Center, Guardian Lifecare, Healthkart, WTS International, The Body Holiday, Bon Vital, Biologique Recherch, MINDBODY Inc., Massage Envy, ClearCost Health, Golds Gym International, Inc., World Gym, Spafinder Wellness 365, Kaya Skin Clinic, Body master and others

Explore Extensive Coverage of PMR`sLife Sciences & Transformational HealthLandscape

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics andmarket research methodologyto help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMRs collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.

Contact us:

Tanvi BirajdarPersistence Market ResearchAddress 305 Broadway, 7th Floor New York City,NY 10007 United StatesU.S. Ph. +1-646-568-7751USA-Canada Toll-free +1 800-961-0353Sales[emailprotected]Websitehttps://www.persistencemarketresearch.com

Originally posted here:
Global Medical Wellness Market to Witness Increased Revenue Growth Owing to Rapid Increase in Demand - Scientect

Bioinformatics involves the development and application of novel informatics techniques in the field of biology. It improves the methods of storing, organizing, retrieving and analyzing biological data. Major activity in bioinformatics is to develop software tools in order to generate useful biological knowledge database. In molecular biology, bioinformatics techniques such as signal processing allow extraction of useful results from large amount of raw data. In the field of genetics it helps in sequencing, annotating genomes and to observe mutations. Bioinformatics study acts a biological literature and developmental data bank for biology related data.

Read Report Overview - https://www.transparencymarketresearch.com/medical-bioinformatics-market.html

Similarly, biomedical informatics is an emerging discipline which defines the study of inventions and implementation of structures, algorithms to improve communication, understanding and managing the medical information. The National Center for Toxicological Research (NCTR) conducts research in bioinformatics and chemo informatics. The bioinformatics tools were created for analysis and integration of genomics, proteomics, metabolomics datasets and transcriptomics.

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=16382

The growth of global medical bioinformatics market is driven by increasing initiatives and funding, use of bioinformatics in drug discovery and biomarkers. The market is expected to offer opportunities with the introduction and adoption of upcoming technologies such as cloud computing and other sequencing technologies. The global medical bioinformatics market can be segmented by tools approved from Food and Drug Administration (FDA) or European Federation for Medical informatics (EFMI) for further research process.

Medical Bioinformatics market is based on the tools, application and end users.

Request for Analysis of COVID-19 Impact on Medical Bioinformatics Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=16382

The global medical bioinformatics market can be segmented based on types of tools and the list of bioinformatics tools approved by FDA are as follows:

Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=16382

The global medical bioinformatics market can be segmented by application as follows:

The global medical bioinformatics market can be segmented by end user as follows:

Medical bioinformatics market is segmented into five major regions: North America, Europe, Latin America, Asia Pacific, and Rest of World. North America leads the market followed by the European nations in terms of revenue. Globally, the medical bioinformatics market growth is expected to increase with the demand in development of generic drug development and mode of sequencing the genes in order to have prevalence from various diseases. In 2015, Department of Biomedical Informatics was inaugurated at Harvard Medical School. This was initiated in order to bring quantitative methods and technological development to biomedicine engineering research. According to Harvard Medical School, Department of Biomedical Informatics (DBMI) and research associates planned to break the wall of autism by detecting the disorder in newborns using the same standard of testing device used to check for hearing impairment. According to Food and Drug Administration, collaboration with National Center for Toxicological Research has driven the demand and use of bioinformatics tools such as predicting patient-specific treatment outcomes with in silico tools. Latin America and Asia Pacific regions are anticipated to be the emerging markets in the global medical bioinformatics market during the forecast period. The effective guidelines from EFMI reports the promotion of high standard application and development in medical bioinformatics. Increase in patient population base and rising disease incidences in the Asia Pacific region is expected to fuel the use of bioinformatics tools for research and tests, which is projected to propel the demand in global medical bioinformatics market in the forecast period.

Pre Book Medical Bioinformatics Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=16382&ltype=S

The key players in the global medical bioinformatics market develop bioinformatics tools, and software which is used in drug designing, sequencing methods. Some of the top players in the global medical bioinformatics market are Optra HEALTH, Affymetrix, Inc., Thermo Fisher Scientific Inc., Illumina, Inc., QIAGEN, Paraxel, Station X and others.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

Browse More Trending Reports by Transparency Market Research:

Liposomal Doxorubicin Market: https://www.transparencymarketresearch.com/liposomal-doxorubicin-market.html

Local Anesthetic Therapeutics Market: https://www.transparencymarketresearch.com/local-anesthetic-therapeutics-market.html

Preclinical CRO Market: https://www.transparencymarketresearch.com/preclinical-cro-market.html

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

ContactMr. Rohit BhiseyTransparency Market ResearchState Tower,90 State Street,Suite 700,Albany NY - 12207United StatesUSA - Canada Toll Free: 866-552-3453Email: sales@transparencymarketresearch.comWebsite: https://www.transparencymarketresearch.com/

The rest is here:
Medical Bioinformatics Market shares and strategies of key players - BioSpace

TAMPA, Fla., Aug. 25, 2020 /PRNewswire/ --M2GEN announced today the launch of its oncology-focused Bioinformatics Support Services. Leveraging the results and knowledge gained from the ORIEN Avatar Program, an extensive, unique and ever-growing oncology clinico-genomics dataset, the M2GEN Bioinformatics team provides bioinformatics support services adhering to best-in-class standards.

M2GEN offers the following bioinformatics services: Paired Tumor and Germline Whole Exome Sequencing (WES) analysis with Panel of Normals (PoN) filtering, Tumor-Only Whole Exome Sequencing (WES) analysis with Virtual Normal (VN) somatic mutation classification, and Tumor-Only RNA Sequencing (RNA-Seq) analysis. Pipeline analysis is WES and RNA-Seq capture kit agnostic, and uses the most up to date human genome reference (GRCh38/hg38) and gene build (Gencode V32). All bioinformatics services are performed in HIPAA compliant and HI Trust certified cloud solutions.

M2GEN Bioinformatics Support Services utilize one of the largest Panel of Normals (PoN) available for high-quality somatic mutation calling. Over 20,000 germline samples from cancer patients inform the segregation of somatic and germline variants, and identify recurrent sequencing artifacts. In addition, the Avatar germline sequencing data is leveraged as a Virtual Normal (VN) cohort during Tumor-Only analysis, allowing for superior somatic mutation classification when patients' matched normal biospecimens are unavailable.

M2GEN's Bioinformatics Support Services are led by an experienced team of bioinformatics and computational biology experts trained at world-renowned scientific institutions such as Baylor College of Medicine Human Genome Sequencing Center, Memorial Sloan Kettering Cancer Center, European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Trust Sanger Institute and Columbia University.

"M2GEN now provides next generation sequencing analysis pipelines to customers in academia and biopharma industry. Our end-to-end bioinformatics solutions and pipelines are tuned for large-scale oncology multi-omics studies that allow our customers to dedicate more time to results interpretation and discovery," said Oliver Hampton PhD, Vice President of Bioinformatics & Biostatistics at M2GEN.

"M2GEN continues to expand its portfolio of data solutions, services, and technologies to be the best partner possible for its clients as we transform cancer care together and make precision medicine a reality," said Helge Bastian, PhD, President & CEO of M2GEN. "M2GEN's bioinformatics services enable researchers in academic and pharmaceutical research worldwide to gain the most meaningful molecular insights in oncology. These molecular insights will accelerate the development of novel and more effective patient specific therapies, turning cancer into a manageable condition, or better still a curable disease."

About M2GEN

M2GEN is an oncology-focused health informatics solutions company with the mission to help patients get access to the best treatments by leveraging clinical and molecular data to accelerate the discovery, development and delivery of tailored and more personalized therapies. M2GEN's approach is to transform cancer care through identifying the genome analysis of patient-derived tumor specimens, and translating new molecular insights combined with clinical insights into individual therapeutics and / or diagnostic tools. For more information, visitM2GEN.com.

SOURCE M2GEN

m2gen.com

Read more:
M2GEN Announces the Launch of its Oncology-Focused Bioinformatics Support Services - PRNewswire

The global report on Whole Exome Sequencing market presents, through a comprehensive analysis, the newly published research study that provides key industry insights and a competitive advantage for multiple stakeholders. Whole Exome Sequencing report shows existing business research, future as well as emerging prospects, sales growth, potential investment, market size, pricing and profitability.

Major Players Covered in this Report are:Eurofins Scientific Group, F. Hoffmann-La Roche AG, Bio-Rad Laboratories Inc., Beijing Genomics Institute, Pacific Biosciences of California Inc., Ambry Genetics Corp., GENEWIZ Inc., Agilent Technologies Inc., Macrogen Inc., Illumina Inc.

Final Whole Exome Sequencing Report will add the analysis of the impact of COVID-19 on this industry.

Request a Sample Copy to Understand the Impact of COVID-19 on Whole Exome Sequencing [emailprotected] https://www.marketgrowthinsight.com/sample/134935

The research on the Global Whole Exome Sequencing market 2020 offers a basic overview of the industry including concepts, classifications, applications and the structure of the supply chain. The Global Whole Exome Sequencing Market Report is given for global markets as well as trends in growth, competitive landscape analysis and the development status of key regions. Whole Exome Sequencing industry Development policies and plans will be discussed as well as processes of manufacturing and cost structures will also be analysed. In addition, Whole Exome Sequencing report includes import/export usage, supply and demand Statistics, expense, price, revenue and gross margins.

Geographically, the detailed analysis of consumption, revenue, Whole Exome Sequencing market share and growth rate, historic and forecast (2015-2026) of the following regions are covered:

North America (United States, Canada, Mexico)Europe (Germany, UK, France, Italy, Spain, Russia, Others)Asia-Pacific (China, Australia,South Korea,Japan, India, Southeast Asia, Others)Middle East and Africa (UAE, Saudi Arabia, Egypt, South Africa, Nigeria, Others)South America (Brazil, Argentina, Columbia, Chile, Others)

To get Incredible Discounts on this Premium [emailprotected] https://www.marketgrowthinsight.com/discount/134935

The Global Whole Exome Sequencing Market Report establish a range of primary and secondary research techniques to collect both quantitative and qualitative data on global and regional heads. Using different Whole Exome Sequencing industry-best analytical techniques, the overwhelming quantity of business data thus obtained is filtered and narrowed down to the Whole Exome Sequencing information that matter most to businesses operating in the sector or planning to enter.

The Whole Exome Sequencing study projects practicability analysis, SWOT analysis, and various other information about the leading companies operating in the Global Whole Exome Sequencing Market provide a detailed systematic account of the competitive environment of the industry with the aid of thorough company profiles. However, Whole Exome Sequencing research examines the impact of current market success and future growth prospects for the industry.

In this study, the years considered to estimate the market size of Whole Exome Sequencing are as follows:

Whole Exome Sequencing research provides answers to the following key questions:

About Us-

Market Growth Insight 100% Subsidiary of Exltech Solutions India, is a one stop solution for market research reports in various business categories. We are serving 100+ clients with 30000+ diverse industry reports and our reports are developed to simplify strategic decision making, on the basis of comprehensive and in-depth significant information, established through wide ranging analysis and latest industry trends.

Contact Us:

Direct Line:+1 3477675477 (US)Email:[emailprotected]Web:https://www.marketgrowthinsight.com

Read more:
Whole Exome Sequencing Market Industry Size, Growth, Analysis and Forecast to 2026 Eurofins Scientific Group, F. Hoffmann-La Roche AG, Bio-Rad...

Honeywell is getting the collaborative spirit:Honeywell, which recently signed a partnership with SAP to help organizations understand the financial performance of their buildings, has signed onto another collaboration, this time with oil services giant Halliburton. The focus here is on both collaboration and bringing data from each companys software to build new products and services. This is where the internet of things can really start to create value, because no one company will have all of the data necessary to document a business process. Its worth paying attention to these deals, noting how well they actually progress and what customers adopt. That way we can track if customers are really buying into the promise of IoT and, in turn, delivering value as part of an ecosystem. (Seeking Alpha)

Were finallyready to talk about standards for consumer wearables for medical-grade use cases: Silicon Valley has rushed to deliver wellness products in the form of activity trackers, sleep trackers, connected blood pressure cuffs, and EKG devices that run on your smartphone. But for the most part, these arent sufficient for medical-grade use cases because the data they produce isnt standardized or consistently tested in peer-reviewed studies. With the rush toward the remote monitoring of patients and remotely conducted clinical trials, the medical device industry is calling for Silicon Valley to help corral the Wild West of Datathat has emerged. In this essay, the authors call for companies to sign on to use standard, clinically validated methodologies for data collecting and sharing so researchers can compare results from patients wearing Fitbits to those wearing Apple Watches. Because while its fine if proprietary algorithms are used for the consumer-facing apps, for clinical trials, there needs to be more transparency. (Stat)

COVID cuts smart home revenue estimates:ABI Research says that in 2020, smart home device spending will rise by 4% from the prior year, to $85 billion. However, the new figure represents a $14.1 billiondecline in predicted sales, since prior to the pandemic analysts expected spending to rise by 21%.This data actually surprised me because it suggests that COVID-19 has cut the adoption of smart home devices despite many of us spending far more time at home. Given that job losses and economic uncertainty make it hard to shell out $50 for a smart light bulb, and that expensive security cameras arent really necessary if you never leave home, I guess the data makes sense. But I also wonder how many people are, like me, tired of reading about privacy violations and devices that lose their functionality and/or have security flaws. (CE Pro)

Its a cardiologist in a box?A startup called Bodyport has raised $11.2 million for its connected scale, which is designed to measure health. The scale is part of an overall medical-grade service that links a patient to their cardiologist and helps both track heart data without the need for in-person visits to a clinic. Im assuming that because of the pandemic the company sees a chance to push its version of sensors and algorithms to the medical industry and the masses. But at this point Im a little burned out by the mess of products competing to provide health monitoring without a focus on creating data standards and new systems for helping doctors manage what will be a huge influx of data.(Bodyport)

This is a fun-sounding startup: Las Vegas-based Terbine is trying to create a real-world market for data. This is a concept Ive been excited about for more than a decade, but technical and logistical challenges seem to keep it forever on the sidelines. On the technical side, some of the challenges include trying to move large amounts of data and the speed at which some data becomes stale. For example, weather data may be relevant for a long time, but theres a lot of it, so transferring it to another party comes with storage and associated bandwidth costs (the data gravity problem). Also, certain data such as traffic light data is only good for a few seconds or minutes, so a market would have to be faster than current ad exchanges. On the logistical side, most companies believe that their data is the new oil and want to hoard it, despite not knowing what to do with it or realizing that it would be more valuable when combined with data from other firms. So Ill keep an eye on Terbine because, as I said, I love this idea. (IMC)

Apptricity releases a Bluetooth tracker that can go the distance: Apptricity has shown off a Bluetooth hub and tracker that can measure a location for 20 miles, far beyond the typical 30-to-100-foot range that Bluetooth radio waves can travel. The boost means that Apptricity Bluetooth devices can compete with SigFox, LoRa, and other Low-Power Wide-Area Networks for tracking devices across large corporate campuses and warehouse settings. (Apptricity)

Personalized medicine could be coming closer:One of the ideas celebrated by futurists is that AI and the IoT can help deliver medical interventions personalized for each individual. This requires pretty intrusive surveillance of your body, but if you could get a customized treatment for your cancer that killed the cancerous cells while minimizing any side effects, youd probably take it. Now UCLA Samueli School of Engineering and the Stanford School of Medicine have built a smartwatch that analyzes a persons sweat to detect trace amounts of medicine in their body. This would allow doctors to calculate the exact amount of a drug that would be effective for each patient possibly reducing both the side effects and cost of treatment. (Medgadget)

This is a deep dive into new ways of performing machine learning on time-series data: For those of yall who are familiar with convolutional neural networks, recurrent neural networksand other ways of training computers to extract meaning from data, this article talks about a new technique that combines different training models and is optimized for time-series data. They are called temporal convolutional networks or TCNs. This is relevant for IoT folks, because a lot of the data generated by sensors is time-series data, and more efficient ways to train algorithms to handle such data could benefit many IoT applications. This is a dense read, but worth it. (Medium)

SiFive just got a lot more money: SiFive, the company making it easier for designers to build RISC-V processors, has raised $61 million in Series E funding, bringing its total funding to about $190 million. The company is banking on a new open-source chip architecture calledRISC-V that competes with MIPS, x86, and the Arm architecture. RISC-V is gaining ground because it doesnt have the high licensing fees associated with some of the other options, and because designers can freely customize it for specific workloads. A few companies are using RISC-V chips to build chips for the IoT.(HPC Wire)

Related

Original post:
IoT news of the week for August 14, 2020 - Stacey on IoT

BOZEMAN, Mont., Aug. 12, 2020 /PRNewswire/ --Golden Helix has secured its reputation as a global leader in Next-Generation Sequencing solutions for over two decades. Today, they have been included in the esteemed Inc. 5000 list of rapidly growing American companies. Out of the 6 million business in the United States, Golden Helix has been honored with a spot in the annual list for the 2nd consecutive year.

Being ranked in the top 5000 places, Golden Helix is among some of the fastest growing and highly respected companies in both size and revenue a testament to the company's focus on innovation, quality, and customer satisfaction.

"We are ecstatic to be named among the country's leading companies. Next-Generation Sequencing is here to stay, and we are very appreciative to be experiencing global adoption of our solution stack," said Dr. Andreas Scherer, President and CEO of Golden Helix. "Our industry-leading CNV analytics capabilities in conjunction with state-of-the-art clinical workflows to diagnose cancer and rare diseases have differentiated ourselves in the marketplace. On top of that, we provide secure and scalable enterprise deployment capabilities with our data warehouse solution."

Of the tens of thousands of companies that have applied over the years, only a fraction of them makes the list more than once. The recognition comes on the heels of Golden Helix also being recognized by Healthcare Tech Outlook on its list of Top 10 Genetic Diagnostics Companies of 2020.

"The whole team at Golden Helix would like to thank each of our customers and partners for helping us become one of the fastest-growing biotech firms in the country," said Dr. Scherer. "I also want to thank the entire team at Golden Helix for all the creativity and dedication over many years in a competitive marketplace. We're honored to receive this recognition among so many remarkable companies."

About Golden Helix

Golden Helix has been delivering industry-leading bioinformatics solutions for the advancement of life science research and translational medicine for over 20 years with 1,000s of users around the world. With their solutions, hundreds of the world's top hospitals, testing labs, pharmaceutical, biotech, and academic research organizations can harness the full potential of genomics to identify the cause of disease, improve the efficacy and safety of drugs, develop genomic diagnostics, and advance the quest for personalized medicine.

Delaina HawkinsGolden Helix, Inc(406) 999-0176[emailprotected]

SOURCE Golden Helix Inc

http://www.goldenhelix.com

More here:
Golden Helix, Inc. Claims Position on Acclaimed Inc. 5000 List of Fastest-Growing Private Companies for Second Year Running - PRNewswire

New Jersey, United States,- Verified Market Researchhas recently published an extensive report on the Personalized Medicine Market to its ever-expanding research database. The report provides an in-depth analysis of the market size, growth, and share of the Personalized Medicine Market and the leading companies associated with it. The report also discusses technologies, product developments, key trends, market drivers and restraints, challenges, and opportunities. It provides an accurate forecast until 2027. The research report is examined and validated by industry professionals and experts.

The report also explores the impact of the COVID-19 pandemic on the segments of the Personalized Medicine market and its global scenario. The report analyzes the changing dynamics of the market owing to the pandemic and subsequent regulatory policies and social restrictions. The report also analyses the present and future impact of the pandemic and provides an insight into the post-COVID-19 scenario of the market.

Personalized Medicine Market was valued at USD 96.97 Billion in 2018 and is expected to witness a growth of10.67% from 2019-2026 and reachUSD 217.90 Billion by 2026.

The report further studies potential alliances such as mergers, acquisitions, joint ventures, product launches, collaborations, and partnerships of the key players and new entrants. The report also studies any development in products, R&D advancements, manufacturing updates, and product research undertaken by the companies.

Leading Key players of Personalized Medicine Market are:

Competitive Landscape of the Personalized Medicine Market:

The market for the Personalized Medicine industry is extremely competitive, with several major players and small scale industries. Adoption of advanced technology and development in production are expected to play a vital role in the growth of the industry. The report also covers their mergers and acquisitions, collaborations, joint ventures, partnerships, product launches, and agreements undertaken in order to gain a substantial market size and a global position.

Regional Analysis of Personalized Medicine Market:

A brief overview of the regional landscape:

From a geographical perspective, the Personalized Medicine Market is partitioned into

North Americao U.S.o Canadao MexicoEuropeo Germanyo UKo Franceo Rest of EuropeAsia Pacifico Chinao Japano Indiao Rest of Asia PacificRest of the World

Key coverage of the report:

Other important inclusions in Personalized Medicine Market:

About us:

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals, and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyze data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (203)-411-9686APAC: +91 (902)-863-5784US Toll-Free: +1 (800)-7821768

Email: [emailprotected]

Continue reading here:
Personalized Medicine Market Size by Top Companies, Regions, Types and Application, End Users and Forecast to 2027 - Bulletin Line

LLS announced today, Rich Pentz and Tina Swallow were awarded the prestigious titles, National Man of the Year and National Woman of the Year, and broke new local campaign records, raising $518,906 and $467,686 respectively. The campaign has helped LLS invest nearly$1.3 billion, ensuring that the organization continues to deliver its cancer curing mission and impact for patients, who need support now, more than ever.

The funds raised through Man & Woman of the Year are used for:

"Cancer will not wait for COVID-19 to go away. And cancer patients can't wait either," said Louis J. DeGennaro, Ph.D., LLS president and CEO. "With the grit and determination of LLS supporters and volunteers like our Man & Woman of the Year candidates, LLS maintains a very significant, impactful mission agenda. We will continue to forge ahead relentlessly to find cures and help blood cancer patients access the care they need."

Pentz, a senior director of institutional sales and relationship management at Principal Global Investors in Indianapolis, IN, spearheaded "Team Echo" after accepting his nomination in memory of his mother, Patricia, who lost her battle to acute myeloid leukemia six years ago. He leveraged social media and organizedinnovative fundraising tactics in lieu of his other event plans, which were canceled due to COVID-19. Pentz said he was "elated beyond words" to find out his campaign, which culminated on his mother's birthday, June 20, broke a new fundraising record for Indiana."It's not about winning the title, it's about the impact we're makingon the cancer landscape," said Pentz.

Swallow, a 21-year Navy veteran and services director at Cisco in Washington, D.C., led "Team Bridge to a Cure" and ran her campaign in honor of her oldest son, Beau, who survived stage 4 cancer. "I've made it my mission to never stop fighting for cancer cures," said Swallow. "Just like LLS, my mission has not changed, what has changed is the urgency for patients."

The National Man & Woman of the Year runners-up were Jesse Giordano of "Team Unity" of Opal Wealth Advisors in Long Island, NY, and Lauren Palmer of "Team Gold" in Charlotte, NC they raised $437,510 and $352,792, respectively. The National "All Star" winners were Brian Fuller of "Team Lexie's Legacy" in Atlanta, GA, and Allison Jockel of "Team AML All Stars" in Charlotte, NC. Collectively, they raised more than $542,192. Fuller broke a new national All Star fundraising record and ran his campaign in memory of Lexie Clayton, a former LLS staff member who passed away from cancer at 36 years old.

To learn more about Man & Woman of the Year, visitwww.mwoy.org.

About The Leukemia & Lymphoma Society

The Leukemia & Lymphoma Society (LLS) is a global leader in the fight against cancer. The LLS mission: cure leukemia, lymphoma, multiplemyeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world, provides free information and support services, and is the voice for all blood cancer patients seeking access to quality, affordable, coordinated care.

Founded in 1949 and headquartered in Rye Brook, NY, LLS has chapters throughout the United States and Canada. To learn more, visit http://www.LLS.org. Patients should contact the Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 9 p.m., ET.

For additional information visitlls.org/lls-newsnetwork. Follow us onFacebook,Twitter, andInstagram.

The LLS Children's Initiative: Cures and Care for Children with Cancer

TheLLS Children's Initiativeis a $100 million multi-year effort to take on children's cancer through every facet of LLS's mission: research, patient education and support and policy and advocacy. The LLS Children's Initiative includes: more pediatric research grants, a global precision medicine clinical trial, expanded free education and support services for children and families and driving policies and laws that break down barriers to care. To learn more, visitwww.lls.org/childrens-initiative.

Media Contact:Kristin Hoose[emailprotected](914) 821-8973

SOURCE The Leukemia & Lymphoma Society (LLS)

http://www.lls.org

See the original post here:
Communities Nationwide Remain Laser-Focused on Helping Cancer Patients Who Can't Wait For Pandemic to Go Away - PRNewswire

Overview of Cancer/ Tumor Profiling Market Report Helps In Providing Scope and Definitions, Key Findings, Growth Drivers, and Various Dynamics.

The global Cancer/ Tumor Profiling market focuses on encompassing major statistical evidence for the Cancer/ Tumor Profiling industry as it offers our readers a value addition on guiding them in encountering the obstacles surrounding the market. A comprehensive addition of several factors such as global distribution, manufacturers, market size, and market factors that affect the global contributions are reported in the study. In addition the Cancer/ Tumor Profiling study also shifts its attention with an in-depth competitive landscape, defined growth opportunities, market share coupled with product type and applications, key companies responsible for the production, and utilized strategies are also marked.

This intelligence and 2026 forecasts Cancer/ Tumor Profiling industry report further exhibits a pattern of analyzing previous data sources gathered from reliable sources and sets a precedented growth trajectory for the Cancer/ Tumor Profiling market. The report also focuses on a comprehensive market revenue streams along with growth patterns, analytics focused on market trends, and the overall volume of the market.

Moreover, the Cancer/ Tumor Profiling report describes the market division based on various parameters and attributes that are based on geographical distribution, product types, applications, etc. The market segmentation clarifies further regional distribution for the Cancer/ Tumor Profiling market, business trends, potential revenue sources, and upcoming market opportunities.

Download PDF Sample of Cancer/ Tumor Profiling Market report @ https://hongchunresearch.com/request-a-sample/58977

Key players in the global Cancer/Tumor Profiling market covered in Chapter 4:Illumina Inc. (U.S.)HTG Molecular Diagnostic (U.S.)Genomic Health Inc. (U.S.)NeoGenomics Laboratories (U.S.)QIAGEN N.V. (Netherlands)

In Chapter 11 and 13.3, on the basis of types, the Cancer/Tumor Profiling market from 2015 to 2026 is primarily split into:Next-generation SequencingIn Situ HybridizationImmunohistochemistryQuantitative PCR

In Chapter 12 and 13.4, on the basis of applications, the Cancer/Tumor Profiling market from 2015 to 2026 covers:Personalized MedicineBiomarker DiscoveryDiagnosticsPrognostics

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2015-2026) of the following regions are covered in Chapter 5, 6, 7, 8, 9, 10, 13:North America (Covered in Chapter 6 and 13)United StatesCanadaMexicoEurope (Covered in Chapter 7 and 13)GermanyUKFranceItalySpainRussiaOthersAsia-Pacific (Covered in Chapter 8 and 13)ChinaJapanSouth KoreaAustraliaIndiaSoutheast AsiaOthersMiddle East and Africa (Covered in Chapter 9 and 13)Saudi ArabiaUAEEgyptNigeriaSouth AfricaOthersSouth America (Covered in Chapter 10 and 13)BrazilArgentinaColumbiaChileOthers

The Cancer/ Tumor Profiling market study further highlights the segmentation of the Cancer/ Tumor Profiling industry on a global distribution. The report focuses on regions of North America, Europe, Asia, and the Rest of the World in terms of developing business trends, preferred market channels, investment feasibility, long term investments, and environmental analysis. The Cancer/ Tumor Profiling report also calls attention to investigate product capacity, product price, profit streams, supply to demand ratio, production and market growth rate, and a projected growth forecast.

In addition, the Cancer/ Tumor Profiling market study also covers several factors such as market status, key market trends, growth forecast, and growth opportunities. Furthermore, we analyze the challenges faced by the Cancer/ Tumor Profiling market in terms of global and regional basis. The study also encompasses a number of opportunities and emerging trends which are considered by considering their impact on the global scale in acquiring a majority of the market share.

The study encompasses a variety of analytical resources such as SWOT analysis and Porters Five Forces analysis coupled with primary and secondary research methodologies. It covers all the bases surrounding the Cancer/ Tumor Profiling industry as it explores the competitive nature of the market complete with a regional analysis.

Brief about Cancer/ Tumor Profiling Market Report with [emailprotected] https://hongchunresearch.com/report/cancer-tumor-profiling-market-2020-58977

Some Point of Table of Content:

Chapter One: Report Overview

Chapter Two: Global Market Growth Trends

Chapter Three: Value Chain of Cancer/Tumor Profiling Market

Chapter Four: Players Profiles

Chapter Five: Global Cancer/Tumor Profiling Market Analysis by Regions

Chapter Six: North America Cancer/Tumor Profiling Market Analysis by Countries

Chapter Seven: Europe Cancer/Tumor Profiling Market Analysis by Countries

Chapter Eight: Asia-Pacific Cancer/Tumor Profiling Market Analysis by Countries

Chapter Nine: Middle East and Africa Cancer/Tumor Profiling Market Analysis by Countries

Chapter Ten: South America Cancer/Tumor Profiling Market Analysis by Countries

Chapter Eleven: Global Cancer/Tumor Profiling Market Segment by Types

Chapter Twelve: Global Cancer/Tumor Profiling Market Segment by Applications12.1 Global Cancer/Tumor Profiling Sales, Revenue and Market Share by Applications (2015-2020)12.1.1 Global Cancer/Tumor Profiling Sales and Market Share by Applications (2015-2020)12.1.2 Global Cancer/Tumor Profiling Revenue and Market Share by Applications (2015-2020)12.2 Personalized Medicine Sales, Revenue and Growth Rate (2015-2020)12.3 Biomarker Discovery Sales, Revenue and Growth Rate (2015-2020)12.4 Diagnostics Sales, Revenue and Growth Rate (2015-2020)12.5 Prognostics Sales, Revenue and Growth Rate (2015-2020)

Chapter Thirteen: Cancer/Tumor Profiling Market Forecast by Regions (2020-2026) continued

Check [emailprotected] https://hongchunresearch.com/check-discount/58977

List of tablesList of Tables and FiguresTable Global Cancer/Tumor Profiling Market Size Growth Rate by Type (2020-2026)Figure Global Cancer/Tumor Profiling Market Share by Type in 2019 & 2026Figure Next-generation Sequencing FeaturesFigure In Situ Hybridization FeaturesFigure Immunohistochemistry FeaturesFigure Quantitative PCR FeaturesTable Global Cancer/Tumor Profiling Market Size Growth by Application (2020-2026)Figure Global Cancer/Tumor Profiling Market Share by Application in 2019 & 2026Figure Personalized Medicine DescriptionFigure Biomarker Discovery DescriptionFigure Diagnostics DescriptionFigure Prognostics DescriptionFigure Global COVID-19 Status OverviewTable Influence of COVID-19 Outbreak on Cancer/Tumor Profiling Industry DevelopmentTable SWOT AnalysisFigure Porters Five Forces AnalysisFigure Global Cancer/Tumor Profiling Market Size and Growth Rate 2015-2026Table Industry NewsTable Industry PoliciesFigure Value Chain Status of Cancer/Tumor ProfilingFigure Production Process of Cancer/Tumor ProfilingFigure Manufacturing Cost Structure of Cancer/Tumor ProfilingFigure Major Company Analysis (by Business Distribution Base, by Product Type)Table Downstream Major Customer Analysis (by Region)Table Illumina Inc. (U.S.) ProfileTable Illumina Inc. (U.S.) Production, Value, Price, Gross Margin 2015-2020Table HTG Molecular Diagnostic (U.S.) ProfileTable HTG Molecular Diagnostic (U.S.) Production, Value, Price, Gross Margin 2015-2020Table Genomic Health Inc. (U.S.) ProfileTable Genomic Health Inc. (U.S.) Production, Value, Price, Gross Margin 2015-2020Table NeoGenomics Laboratories (U.S.) ProfileTable NeoGenomics Laboratories (U.S.) Production, Value, Price, Gross Margin 2015-2020Table QIAGEN N.V. (Netherlands) ProfileTable QIAGEN N.V. (Netherlands) Production, Value, Price, Gross Margin 2015-2020Figure Global Cancer/Tumor Profiling Sales and Growth Rate (2015-2020)Figure Global Cancer/Tumor Profiling Revenue ($) and Growth (2015-2020)Table Global Cancer/Tumor Profiling Sales by Regions (2015-2020)Table Global Cancer/Tumor Profiling Sales Market Share by Regions (2015-2020)Table Global Cancer/Tumor Profiling Revenue ($) by Regions (2015-2020)Table Global Cancer/Tumor Profiling Revenue Market Share by Regions (2015-2020)Table Global Cancer/Tumor Profiling Revenue Market Share by Regions in 2015Table Global Cancer/Tumor Profiling Revenue Market Share by Regions in 2019Figure North America Cancer/Tumor Profiling Sales and Growth Rate (2015-2020)Figure Europe Cancer/Tumor Profiling Sales and Growth Rate (2015-2020)Figure Asia-Pacific Cancer/Tumor Profiling Sales and Growth Rate (2015-2020)Figure Middle East and Africa Cancer/Tumor Profiling Sales and Growth Rate (2015-2020)Figure South America Cancer/Tumor Profiling Sales and Growth Rate (2015-2020)Figure North America Cancer/Tumor Profiling Revenue ($) and Growth (2015-2020)Table North America Cancer/Tumor Profiling Sales by Countries (2015-2020)Table North America Cancer/Tumor Profiling Sales Market Share by Countries (2015-2020)Figure North America Cancer/Tumor Profiling Sales Market Share by Countries in 2015Figure North America Cancer/Tumor Profiling Sales Market Share by Countries in 2019Table North America Cancer/Tumor Profiling Revenue ($) by Countries (2015-2020)Table North America Cancer/Tumor Profiling Revenue Market Share by Countries (2015-2020)Figure North America Cancer/Tumor Profiling Revenue Market Share by Countries in 2015Figure North America Cancer/Tumor Profiling Revenue Market Share by Countries in 2019Figure United States Cancer/Tumor Profiling Sales and Growth Rate (2015-2020)Figure Canada Cancer/Tumor Profiling Sales and Growth Rate (2015-2020)Figure Mexico Cancer/Tumor Profiling Sales and Growth (2015-2020)Figure Europe Cancer/Tumor Profiling Revenue ($) Growth (2015-2020)Table Europe Cancer/Tumor Profiling Sales by Countries (2015-2020)Table Europe Cancer/Tumor Profiling Sales Market Share by Countries (2015-2020)Figure Europe Cancer/Tumor Profiling Sales Market Share by Countries in 2015Figure Europe Cancer/Tumor Profiling Sales Market Share by Countries in 2019Table Europe Cancer/Tumor Profiling Revenue ($) by Countries (2015-2020)Table Europe Cancer/Tumor Profiling Revenue Market Share by Countries (2015-2020)Figure Europe Cancer/Tumor Profiling Revenue Market Share by Countries in 2015Figure Europe Cancer/Tumor Profiling Revenue Market Share by Countries in 2019Figure Germany Cancer/Tumor Profiling Sales and Growth Rate (2015-2020)Figure UK Cancer/Tumor Profiling Sales and Growth Rate (2015-2020)Figure France Cancer/Tumor Profiling Sales and Growth Rate (2015-2020)Figure Italy Cancer/Tumor Profiling Sales and Growth Rate (2015-2020)Figure Spain Cancer/Tumor Profiling Sales and Growth Rate (2015-2020)Figure Russia Cancer/Tumor Profiling Sales and Growth Rate (2015-2020)Figure Asia-Pacific Cancer/Tumor Profiling Revenue ($) and Growth (2015-2020)Table Asia-Pacific Cancer/Tumor Profiling Sales by Countries (2015-2020)Table Asia-Pacific Cancer/Tumor Profiling Sales Market Share by Countries (2015-2020)Figure Asia-Pacific Cancer/Tumor Profiling Sales Market Share by Countries in 2015Figure Asia-Pacific Cancer/Tumor Profiling Sales Market Share by Countries in 2019Table Asia-Pacific Cancer/Tumor Profiling Revenue ($) by Countries (2015-2020)Table Asia-Pacific Cancer/Tumor Profiling Revenue Market Share by Countries (2015-2020)Figure Asia-Pacific Cancer/Tumor Profiling Revenue Market Share by Countries in 2015Figure Asia-Pacific Cancer/Tumor Profiling Revenue Market Share by Countries in 2019Figure China Cancer/Tumor Profiling Sales and Growth Rate (2015-2020)Figure Japan Cancer/Tumor Profiling Sales and Growth Rate (2015-2020)Figure South Korea Cancer/Tumor Profiling Sales and Growth Rate (2015-2020)Figure Australia Cancer/Tumor Profiling Sales and Growth Rate (2015-2020)Figure India Cancer/Tumor Profiling Sales and Growth Rate (2015-2020)Figure Southeast Asia Cancer/Tumor Profiling Sales and Growth Rate (2015-2020)Figure Middle East and Africa Cancer/Tumor Profiling Revenue ($) and Growth (2015-2020) continued

About HongChun Research:HongChun Research main aim is to assist our clients in order to give a detailed perspective on the current market trends and build long-lasting connections with our clientele. Our studies are designed to provide solid quantitative facts combined with strategic industrial insights that are acquired from proprietary sources and an in-house model.

Contact Details:Jennifer GrayManager Global Sales+ 852 8170 0792[emailprotected]

NOTE: Our report does take into account the impact of coronavirus pandemic and dedicates qualitative as well as quantitative sections of information within the report that emphasizes the impact of COVID-19.

As this pandemic is ongoing and leading to dynamic shifts in stocks and businesses worldwide, we take into account the current condition and forecast the market data taking into consideration the micro and macroeconomic factors that will be affected by the pandemic.

Read more here:
Impact Of Covid-19 on Cancer/ Tumor Profiling Market 2020 Industry Challenges, Business Overview and Forecast Research Study 2026 - The Daily...

Written by AZoRoboticsAug 14 2020

Researchers from the Eye Clinic of the University Hospital Bonn, Stanford University, and the University of Utah have developed an artificial intelligence (AI)-based software that enables the accurate evaluation of the progression of geographic atrophy (GA).

Geographic atrophy is a disease of the light-sensitive retina that occurs due to age-related macular degeneration (AMD).

This novel technique enables fully automated measurement of the main atrophic lesions with the help of data obtained from optical coherence tomography, which offers three-dimensional visualization of the retinas structure.

Moreover, the researchers can accurately identify the integrity of light-sensitive cells of the whole central retina, as well as detect progressive degenerative variations of what are called the photoreceptors beyond the main lesions.

The study results will be used to evaluate the effectiveness of new innovative therapeutic approaches. The study was published recently in the JAMA Ophthalmology journal.

Currently, there exists no viable treatment for geographic atrophy, which is one of the most common reasons for blindness in industrialized nations. The disease impairs the cells of the retina and destroys them.

The main lesions, regions of the degenerated retina, also called geographic atrophy, tend to expand with the progression of the disease and lead to blind spots in the visual field of the patient. A main difficulty faced in the case of assessment therapies is that the lesions tend to progress gradually, implying that a long follow-up period is required for intervention studies.

When evaluating therapeutic approaches, we have so far concentrated primarily on the main lesions of the disease. However, in addition to central visual field loss, patients also suffer from symptoms such as a reduced light sensitivity in the surrounding retina.

Dr Frank G. Holz, Professor and Director, Eye Clinic, University Hospital Bonn.

Dr Holz added, Preserving the microstructure of the retina outside the main lesions would therefore already be an important achievement, which could be used to verify the effectiveness of future therapeutic approaches.

Moreover, the researchers could demonstrate that the integrity of light-sensitive cells exterior to the geographic atrophy areas is a predictor of the future progression of the disease.

It may therefore be possible to slow down the progression of the main atrophic lesions by using therapeutic approaches that protect the surrounding light sensitive cells.

Monika Fleckenstein, Professor, Moran Eye Center, University of Utah

Prof. Fleckenstein is the initiator of the Bonn-based natural history study on geographic atrophy, based on which this study was performed.

Research in ophthalmology is increasingly data-driven. The fully automated, precise analysis of the finest, microstructural changes in optical coherence tomography data using AI represents an important step towards personalized medicine for patients with age-related macular degeneration.

Dr Maximilian Pfau, Study Lead Author, Eye Clinic, University Hospital Bonn

Dr Pfau, who is currently a fellow of the German Research Foundation (DFG) and postdoctoral fellow at Stanford University in the Department of Biomedical Data Science, added that It would also be useful to re-evaluate older treatment studies with the new methods in order to assess possible effects on photoreceptor integrity.

Pfau, M., et al. (2020) Progression of Photoreceptor Degeneration in Geographic Atrophy Secondary to Age-related Macular Degeneration. JAMA Ophthalmology. doi.org/10.1001/jamaophthalmol.2020.2914.

Source: https://www.uni-bonn.de/en?set_language=en

Continue reading here:
New AI-Based Software Precisely Assesses Progression of Retinal Legions from Geographic Atrophy - AZoRobotics

DUBLIN--(BUSINESS WIRE)--The "Global DNA Sequencing Market: Growth, Trends & Forecast 2020-2025" report has been added to ResearchAndMarkets.com's offering.

The Global DNA Sequencing Market is expected to witness a CAGR of 18.9% during the forecast period.

Certain factors that are driving the market growth include the rise in technological advancements in DNA sequencing, increasing application in clinical diagnosis & drug discovery, and growing investment in R&D.

The technological advancements in sequencing, from 2D sequencing in the 1970's to DNA sequencing, has come a long way. In the recent years, platforms, such as Illumina/ Solexa, ABI/ SOLiD, 454/Roche, and Helicos, have provided unique prospects for high-throughput functional genomic research. After the introduction of NGS technologies in 2005, they have had an incredible influence on genomic research.

Next-generation sequencing, currently, has its application in the diagnosis of a variety of illnesses, such as cancer, hematological disorders, neurology, psychiatry, dysmorphology, vision and hearing impairment, cardiology, and pharmacogenomics. It is also used as a tool for noninvasive prenatal tests. NGS technologies have been used for standard sequencing applications, like genome sequencing and for novel applications that were previously unexplored by using Sanger sequencing.

Applications include whole genome and transcriptome sequencing, metagenomic characterization of microbial types in environmental and clinical specimens, explanation of DNA binding sites for chromatin and regulatory proteins, and targeted re-sequencing of specific sites in the human genome, identified by linkage analyses.

Key Market Trends

Next Generation Sequencing is Expected to Show Lucrative Growth Opportunity in the Platform Segment

Next Generation Sequencing can be of several types based on the technology. For example, the benefits offered by whole genome sequencing technique, such as ease of handling, affordability, and accuracy, are expected to boost their demand. Additionally, these tests are usually preferred by the market players as a single test, which is capable of providing information on multiple factors, such as virulence, serotype, and resistance.

FDA is applying NGS in innovative ways, which can help reduce foodborne illnesses and deaths. Isolation of pathogens from food or environmental samples may be compared to clinical isolates from patients. A reliable link between the two is made, which helps define the scope of a foodborne illness outbreak. Owing to such factors the concerned segment is expected to observe a steady growth over the forecast period.

North America Dominates the Market and Expected to do Same in the Forecast Period

The North America dominated the global market studied, in 2018, owing to the increasing funding and support activities by the government and non-government entities, especially in the United States. By supporting genomics research, various government bodies, like NHGRI (National Human Genome Research Institute) have supported the work on sequencing of the human genome, and fund research on the genome's structure, function, and role in health and disease.

They also support studies on the ethical, legal, and social implications (ELSI) of genome research. The US National Human Genome Research Institute and the US National Academy of Medicine, organized 90 leaders in genomic medicine from the United States, and 25 other countries in Genomic Medicine Symposium in 2014, in order to identify opportunities for collaborations that promote the responsible practice of genomic medicine.

Competitive Landscape

The DNA Sequencing market is highly competitive and consists of a few major players. Companies like Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Danaher Corporation, Eurofins Scientific, F. Hoffmann-La Roche, Illumina, Inc., Merck KGaA, Pacific Biosciences of California, Inc., PerkinElmer Inc., Thermo Fisher Scientific, Inc., among others, hold the substantial market share in the DNA Sequencing market.

Key Topics Covered

1 INTRODUCTION

1.1 Study Deliverables

1.2 Study Assumptions

1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

4.1 Market Overview

4.2 Market Drivers

4.2.1 Rise in Technological Advancements in DNA Sequencing

4.2.2 Increasing Application in Clinical Diagnosis & Drug Discovery

4.2.3 Growing Investment in R&D

4.3 Market Restraints

4.3.1 Interpretation of Complex Data and Lack of Skilled Professionals

4.3.2 Legal and Ethical Issues

4.4 Porter's Five Force Analysis

5 MARKET SEGMENTATION

5.1 Product Type

5.1.1 Instruments

5.1.2 Consumables (Kits, Reagents)

5.1.3 Others

5.2 Platform

5.2.1 Sanger

5.2.2 Next Generation Sequencing

5.2.3 qPCR

5.2.4 Others

5.3 Application

5.3.1 Diagnostics

5.3.2 Personalized Medicine

5.3.3 Others (Biomarkers, Forensics, Reproductive Health etc.)

5.4 End User

5.4.1 Hospitals and Healthcare Organizations

5.4.2 Academics and Research Institutions

5.4.3 Pharmaceutical and Biotechnology Companies

5.4.4 Others

5.5 Geography

5.5.1 North America

5.5.2 Europe

5.5.3 Asia Pacific

5.5.4 Middle East and Africa

5.5.5 South America

6 COMPETITIVE LANDSCAPE

6.1 Company Profiles

6.1.1 Agilent Technologies, Inc.

6.1.2 Bio-Rad Laboratories, Inc.

6.1.3 Danaher Corporation (Beckman Coulter, Inc.)

6.1.4 Eurofins Scientific

6.1.5 F. Hoffmann-La Roche

6.1.6 Illumina, Inc.

6.1.7 Merck KGaA

6.1.8 Pacific Biosciences of California, Inc.

6.1.9 PerkinElmer Inc.

6.1.10 Thermo Fisher Scientific, Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

For more information about this report visit https://www.researchandmarkets.com/r/29pmu9

Read this article:
DNA Sequencing Industry Outlook 2020-2025 - Increasing Application in Clinical Diagnosis & Drug Discovery is Driving Growth -...

The "Healthcare Descriptive Analysis Market: Growth, Trends and Forecasts (2020-2025)" report has been added to ResearchAndMarkets.com's offering.

Increasing need to reduce healthcare expenditure, including cost associated with medical product flaws and hospital workflow inefficiencies, is anticipated to increase the usage of big data in the healthcare sector.

The digitalization of healthcare data is also one of the primary drivers of healthcare analytics. According to Intel, approximately more than 80% of the healthcare organizations in the U.S. have adopted Electronic Medical Records (EMR) systems. These systems collect a lot of data, which can be analyzed using various types of healthcare analytics to develop personalized medicine.

Advanced methods such as predictive analytics are widely used in government organizations such as healthcare financing systems primarily to avoid frauds in payments. For instance, in 2011, the Centers of Medicare and Medicaid Services (CMS) reported that under its Fraud Prevention System (FPS), predictive analytics helped in saving USD 1.5 billion through improper payments. Moreover, the CMS is developing next generation predictive analytics, which is expected to boost the usage of predictive analytics.

Key Market Trends

Financial Data Analytics Segment Expected to Dominate the Market Over the Forecast Years

By application, the market has been segmented into clinical, financial, administrative, and research data analytics. The Financial Data Analytics segment is expected to register significant growth during the forecast period due to the technologically advanced solutions by healthcare providers and increased focus of payers on the early detection of fraud and reducing preventable costs.

North America Expected to Dominate the World Market

North America is expected to dominate the market followed by Europe. Factors, such as growing federal healthcare mandates to curb rising healthcare costs and provide quality care; increasing regulatory requirements; growing EHR adoption; and rising government initiatives focusing on personalized medicine, population health management, and value-based reimbursements are expected to drive market growth in North America.

Competitive Landscape

The Healthcare Descriptive Analysis market is moderately competitive and many of the global players are into the market. For instance - IBM, Inovalon, Cerner Corporation, Oracle Corporation, McKesson Corporation, MedeAnalytics, Inc., Optum, Inc., Allscripts Healthcare Solutions, Inc., etc. are providing healthcare descriptive analysis products across the globe.

Key Topics Covered

1 INTRODUCTION

1.1 Study Deliverables

1.2 Study Assumptions

1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

4.1 Market Overview

4.2 Market Drivers

4.2.1 Need for Comprehensive Analytics

4.2.2 Integration of Big Data into Healthcare

4.3 Market Restraints

4.3.1 Data Privacy and Security Concerns

4.3.2 High Costs of Initial Investment

4.4 Porter's Five Force Analysis

5 MARKET SEGMENTATION

5.1 By Application

5.1.1 Clinical Data Analytics

5.1.2 Financial Data Analytics

5.1.3 Administrative Data Analytics

5.1.4 Research Data Analytics

5.2 By Component

5.2.1 Software

5.2.2 Hardware

5.2.3 Services

5.3 By Deployment

5.3.1 On-Premise

5.3.2 Web-based

5.3.3 Cloud based

5.4 By End-user

5.4.1 Private organization

5.4.1.1 Hospitals

5.4.1.2 Physicians

5.4.1.3 Clinics

5.4.1.4 Others

5.5 Geography

5.5.1 North America

5.5.1.1 United States

5.5.1.2 Canada

5.5.1.3 Mexico

5.5.2 Europe

5.5.2.1 Germany

5.5.2.2 UK

5.5.2.3 France

5.5.2.4 Italy

5.5.2.5 Spain

5.5.2.6 Rest of Europe

5.5.3 Asia-Pacific

5.5.3.1 China

5.5.3.2 Japan

5.5.3.3 India

5.5.3.4 Australia

5.5.3.5 South Korea

5.5.3.6 Rest of Asia-Pacific

5.5.4 Middle-East and Africa

5.5.4.1 GCC

5.5.4.2 South Africa

5.5.4.3 Rest of Middle-East and Africa

5.5.5 South America

5.5.5.1 Brazil

5.5.5.2 Argentina

5.5.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

6.1 Company Profiles

6.1.1 IBM

6.1.2 Allscripts Healthcare Solutions, Inc.

6.1.3 Cerner Corporation

6.1.4 Inovalon

6.1.5 McKesson Corporation

6.1.6 MedeAnalytics, Inc.

6.1.7 Optum

6.1.8 Oracle Corporation

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

For more information about this report visit https://www.researchandmarkets.com/r/iflgkx

View source version on businesswire.com: https://www.businesswire.com/news/home/20200811005670/en/

Go here to see the original:
Healthcare Descriptive Analysis Industry 2020-2025: Financial Data Analytics Expected to Dominate Over the Forecast Period - ResearchAndMarkets.com -...

The Biomarkers market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

Our analysts monitoring the situation around the Globe explain that after COVID-19 crisis the market will generate remunerative prospects for producers. The goal of the report is to provide a further illustration of the current scenario, economic slowdown and effect of COVID-19 on the industry as a whole.

Biomarkers Market was valued at USD 36.3 Billion in 2018 and expected to reach USD 91.4 Billion by 2025 with a CAGR of 14.1% during the forecast period. Increasing prevalence of cancer and growing precision medicine market are amongst the pivotal factors anticipated to spur the growth of Biomarkers Market.

The global biomarkers market is witnessing a healthy growth trajectory attributed to the growing application of biomarkers in diagnostics, increasing funding for biomarkers research, as well as its rising usage in drug discovery. Biomarkers are biological molecules found in body fluids and tissues that help in crucial clinical decision making and diagnosing various health conditions of the patients. Since the molecules can analyze pharmacological responses and pathological indications, they can effectively assist in process of drug discovery and development.

The diagnostics industry has been witnessing a shift in trend from using conventional diagnostic tools towards using more advanced diagnostic methods that focus on producing accurate and consistent results during early stage of diseases. This has led to boost in demand for biomarkers which are minimally or non-invasive tools to detect diseases such as cancer at early stage. Moreover, growing usage of precision medicine should further boost the biomarkers market growth.

Apart from this, expediting growth in the healthcare IT industry and low costs of clinical trials in emerging countries has favored the entry of various new players in the market. A large chunk of funding is being invested in research and development for new product launches. For instance, in March 2018, Genomic Health, Inc. launched the Oncotype DX AR-V7 Nucleus Detect test. The AR-V7 protein is a prognostic and predictive biomarker. This test aids physicians in taking therapeutic decisions in patients suffering from metastatic castration-resistant prostate cancer (mCRPC) by accurately detecting a splice variant of the androgen receptor protein (AR-V7) in the nucleus of circulating tumor cells (CTCs).

Recent Developments In May 2019, Qiagen announced the immediate launch of its first companion diagnostics assay therascreen PIK3CA RGQ PCR Kit (therascreen PIK3CA Kit) post U.S. FDA regulatory approval as a companion diagnostic to assist in diagnosing breast cancer patients that would be eligible for treatment with newly approved therapy PIQRAY (alpelisib) developed and marketed by Novartis.

Key Players in Biomarkers Market Some of the major players operating in the Global Biomarkers Market include Siemens Healthineers, Medtronic, F. Hoffman LA Roche Ltd., Abbott Laboratories Nexus-DX, Qiagen N.V., PerkinElmer, Inc., Lifesign LLC., Merck & Co, Inc., Bio-Rad Laboratories, EKF Diagnostics Holdings plc, Singulex, Inc., Signosis, Inc, and BioSims Technologies among others.

Global Biomarkers market is segmented on the basis of product, type, application, and disease indication. The Global Biomarkers Market by product includes consumables, services, and software, while based on type the industry is segmented into safety, efficacy, and validation. By application market segmentation includes diagnostics, drug development, personalized medicine, and disease risk assessment. Biomarkers market by disease indication comprises of cancer, cardiovascular diseases, neurological diseases, immunological diseases, and others.

Increasing incidence of cancer and growing precision medicine market are some of the pivotal factors boosting the Biomarkers market growth. Increasing incidence of cancer is one of the pivotal factors which is set to drive the growth of Biomarkers Market. According to World Health Organization (WHO) statistics, various types of cancer accounted for more than 9.5 million deaths in 2018 worldwide. Cancer biomarkers are released by cancer causing tumors that can be detected in blood stream and other tissues, thus helping in early clinical evaluation and deciding the course of treatment.

Moreover, the World Health Assembly has passed the resolution in 2017 for Cancer Prevention and Control. This integrated approach (WHA70.12) has recommended the governments and WHO to speed up action plans specified in the Global Action Plan and 2030 UN Agenda for Sustainable Development to reduce premature mortality from cancer. This has led to a boost in demand for early cancer screening tests and procedures. Increasing focus of research institutes to develop such biomarkers is likely to spur the global Biomarkers Market growth.

Geographically, this report split global into several key Regions, revenue (Million USD) The geography (North America, Europe, Asia-Pacific, Latin America and Middle East & Africa) focusing on key countries in each region. It also covers market drivers, restraints, opportunities, challenges, and key issues in Global Biomarkers Market.

Key Benefits for Biomarkers Market Reports Global market report covers in-depth historical and forecast analysis. Global market research report provides detail information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Market Drivers, Market Restraints, Market Opportunities, Competitive Analysis, Regional and Country Level. Global market report helps to identify opportunities in market place. Global market report covers extensive analysis of emerging trends and competitive landscape.

By Product:ConsumablesServicesSoftware

By Type: SafetyEfficacyValidation

By Application:DiagnosticsDrug DevelopmentPersonalized MedicineDisease Risk Assessment

By Disease Indication:CancerCardiovascular DiseasesNeurological DiseasesImmunological DiseasesOthers

By Region North Americao U.S.o Canadao Mexico Europeo UKo Franceo Germanyo Russiao Rest of Europe Asia-Pacifico Chinao South Koreao Indiao Japano Rest of Asia-Pacific LAMEAo Latin Americao Middle Easto Africa

North America grabbed the largest share in Biomarkers Market globally In 2018, North America accounted for the largest share in the global biomarkers market owing to increasing adoption of precision medicine and rising prevalence of cancer in the region. The largest share of the region is also attributed to the rise in number of cancer cases in the U.S. and launch of Precision Medicine Initiative (PMI) by the U.S. government in 2015. According to the National Cancer Institute statistics, more than 16.5 million cases of cancer were diagnosed in 2016 in the U.S, and this number is expected to reach to 19 million in 2024.

The increasing application of biomarkers in the field of precision medicine should also drive the market in this region. Identification of biomarkers is essential for the development of precision medicine. The U.S. precision medicine industry has been booming post the launch of Precision Medicine Initiative by the government in 2015. The initiative aimed at improving the treatment outcome by offering tailor made therapies to patients. This has spurred the development of novel treatments and drugs based on an individuals genetic profile and characteristics of tumor. The Asia Pacific Biomarkers market is set to showcase lucrative growth in the coming years due to vast patient pool, increasing awareness regarding early disease detection and rising healthcare expenditure in the emerging countries of India and China.

Biomarkers Market Key Players: Siemens Healthineers Medtronic F. Hoffman LA Roche Ltd. Abbott Laboratories Nexus-DX Qiagen N.V. PerkinElmer, Inc. Lifesign LLC. Merck & Co, Inc. Bio-Rad Laboratories EKF Diagnostics Holdings plc Others

This comprehensive report will provide: Enhance your strategic decision making Assist with your research, presentations and business plans Show which emerging market opportunities to focus on Increase your industry knowledge Keep you up-to-date with crucial market developments Allow you to develop informed growth strategies Build your technical insight Illustrate trends to exploit Strengthen your analysis of competitors Provide risk analysis, helping you avoid the pitfalls other companies could make Ultimately, help you to maximize profitability for your company.

Our Market Research Solution Provides You Answer to Below Mentioned Question: Which are the driving factors responsible for the growth of market? Which are the roadblock factors of this market? What are the new opportunities, by which market will grow in coming years? What are the trends of this market? Which are main factors responsible for new product launch? How big is the global & regional market in terms of revenue, sales and production? How far will the market grow in forecast period in terms of revenue, sales and production? Which region is dominating the global market and what are the market shares of each region in the overall market in 2017? How will each segment grow over the forecast period and how much revenue will these segment account for in 2025? Which region has more opportunities?

Table of Content1 Study Coverage1.1 Biomarkers Product1.2 Key Market Segments in This Study1.3 Key Manufacturers Covered1.4 Market by Type1.5 Market by Application1.6 Study Objectives1.7 Years Considered

2 Executive Summary2.1 Global Biomarkers Market Size2.1.1 Global Biomarkers Revenue 2014-20252.1.2 Global Biomarkers Production 2014-20252.2 Biomarkers Growth Rate (CAGR) 2020-20252.3 Analysis of Competitive Landscape2.3.1 Manufacturers Market Concentration Ratio2.3.2 Key Biomarkers Manufacturers2.3.2.1 Biomarkers Manufacturing Base Distribution, Headquarters2.3.2.2 Manufacturers Biomarkers Product Offered2.3.2.3 Date of Manufacturers Enter into Biomarkers Market2.4 Key Trends for Biomarkers Markets & Products

3 Market Size by Manufacturers3.1 Biomarkers Production by Manufacturers3.1.1 Biomarkers Production by Manufacturers3.1.2 Biomarkers Production Market Share by Manufacturers3.2 Biomarkers Revenue by Manufacturers3.2.1 Biomarkers Revenue by Manufacturers (2014-2020)3.2.2 Biomarkers Revenue Share by Manufacturers (2014-2020)3.3 Biomarkers Price by Manufacturers3.4 Mergers & Acquisitions, Expansion Plans

4 Biomarkers Production by Regions4.1 Global Biomarkers Production by Regions4.1.1 Global Biomarkers Production Market Share by Regions4.1.2 Global Biomarkers Revenue Market Share by Regions4.2 North America4.2.1 North America Biomarkers Production4.2.2 North America Biomarkers Revenue4.2.3 Key Players in North America4.2.4 North America Biomarkers Import & Export4.3 Europe4.3.1 Europe Biomarkers Production4.3.2 Europe Biomarkers Revenue4.3.3 Key Players in Europe4.3.4 Europe Biomarkers Import & Export4.4 China4.4.1 China Biomarkers Production4.4.2 China Biomarkers Revenue4.4.3 Key Players in China4.4.4 China Biomarkers Import & Export4.5 Japan4.5.1 Japan Biomarkers Production4.5.2 Japan Biomarkers Revenue4.5.3 Key Players in Japan4.5.4 Japan Biomarkers Import & Export

5 Biomarkers Consumption by Regions5.1 Global Biomarkers Consumption by Regions5.1.1 Global Biomarkers Consumption by Regions5.1.2 Global Biomarkers Consumption Market Share by Regions5.2 North America5.2.1 North America Biomarkers Consumption by Application5.2.2 North America Biomarkers Consumption by Countries5.2.3 United States5.2.4 Canada5.2.5 Mexico5.3 Europe5.3.1 Europe Biomarkers Consumption by Application5.3.2 Europe Biomarkers Consumption by Countries5.3.3 Germany5.3.4 France5.3.5 UK5.3.6 Italy5.3.7 Russia5.4 Asia Pacific5.4.1 Asia Pacific Biomarkers Consumption by Application5.4.2 Asia Pacific Biomarkers Consumption by Regions5.4.3 China5.4.4 Japan5.4.5 South Korea5.4.6 India5.4.7 Australia5.4.8 Indonesia5.4.9 Thailand5.4.10 Malaysia5.4.11 Philippines

About Us: Brandessence Market Research and Consulting Pvt. ltd.

Brandessence market research publishes market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students. We have a delivery center in Pune, India and our sales office is in London.

Contact us at: +44-2038074155 or mail us at [emailprotected]

Blog: https://businessstatsnews.com

Blog: http://www.dailyindustrywatch.com

Blog: https://marketsize.biz

Blog: https://technologyindustrynews.com

Blog: https://marketstatsreport.com

Top Trending Reports:

https://www.marketwatch.com/press-release/tart-cherry-market-size-share-from-2020-to-2025-growth-forecast-analysis-by-manufacturers-type-and-application-2020-08-13?tesla=y

https://www.marketwatch.com/press-release/global-gaming-hardware-market-2020-industry-analysis-by-share-trends-growth-factors-cagr-status-growth-opportunities-segmentation-and-forecast-2025-2020-08-13?tesla=y

https://www.marketwatch.com/press-release/obsessive-compulsive-disorder-ocd-market-2020-growth-analysis-share-demand-types-top-key-players-and-forecast-to-2025-2020-08-13?tesla=y

https://www.marketwatch.com/press-release/geocells-market-size-revenue-analysis-growth-opportunities-and-forecast-2025-strata-systems-inc-wrekin-products-ltd-armtec-infrastructure-inc-maccaferri-spa-ace-2020-08-13?tesla=y

https://www.marketwatch.com/press-release/at-1150-cagr-biophotonics-market-size-to-surpass-usd-8908-billion-by-2025-forecast-by-applications-dynamics-development-status-and-outlook-2025-2020-08-13?tesla=y

Read the original here:
Outlook on the Worldwide Biomarkers Industry to 2025 Scientect - Scientect